Anticonvulsant activity of some schiff bases synthesized from 2- Aminopyridine

Pharmacologyonline

Volumn 2, Issue , 2009, Pages 1048-1074

  Pandey, Shailendra ^a   Srivastava, R S ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

2 Aminopyridine; Anticonvulsant agents; Maximal electro shock; Pentylenetetrazole; Strychnine

Indexed keywords

1,2 DIPHENYL 2 (PYRIDIN 2 YLIMINO)ETHANOL; 2 [(PYRIDIN 2 YLIMINO)METHYL]PHENOL; 2 AMINOPYRIDINE DERIVATIVE; 2 METHOXY 4 [(PYRIDIN 2 YLIMINO)METHYL]PHENOL; ANTICONVULSIVE AGENT; N (1 PHENYLETHYLIDENE)PYRIDIN 2 AMINE; N (1,7,7 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YLIDENE)PYRIDIN 2 AMINE; N (2 CHLOROBENZYLIDENE)PYRIDINE 2 AMINE; N (2 NITROBENZYLIDENE)PYRIDIN 2 AMINE; N (3,4 DIMETHYLBENZYLIDENE)PYRIDIN 2 AMINE; N (3,4,5 TRIMETHOXYBENZYLIDENE)PYRIDIN 2 AMINE; N (3,7 DIMETHYLOCTA 2,6 DIENYLIDENE)PYRIDIN 2 AMINE; N (4 NITROBENZYLIDENE)PYRIDIN 2 AMINE; N (DIPHENYLMETHYLENE)PYRIDIN 2 AMINE; N [(1H INDOL 3 YL)METHYLENE]PYRIDIN 2 AMINE; N [1 (4 AMINOPHENYL)ETHYLIDENE]PYRIDIN 2 AMINE; N BENZYLIDENEPYRIDIN 2 AMINE; N CYCLOHEXYLIDENE PYRIDIN 2 AMINE; N CYCLOPENTYLIDENE PYRIDIN 2 AMINE; PHENOBARBITAL; PHENYL N PYRIDIN 2 YL FORMIMIDATE; PHENYTOIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; INFRARED SPECTROSCOPY; MOUSE; NEUROTOXICITY; NONHUMAN; POLYMERIZATION; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; ROTAROD TEST; TONIC CLONIC SEIZURE;

EID: 70349168675     PISSN: None     EISSN: 18278620     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Brown TR, Holmes GL. Epilapsy N Engl J Med 2001; 344:1145-1151.
2. Salimon J, Salih N, Hussien H, Yousif E. Synthesis and characterization of new heterocyclic compounds derived from 2-aminopyridine. Euro J Sci Res 2009; 312:256-264.
3. Leonard JT, Anbalagan N, Kumar SS, Gnanasam SK, Sridhar SK. Synthesis and pharmacological activities of 2- (3′-substituted-2′-hydroxypropylamino) pyridines. Biol Pharm Bull 2002; 25:2, 215-217.
4. Narendar P, Pratiban J, Anbalagan N, Gunasekaran V, Leonard JT. Pharmacological evaluation of some new 2-substituted pyridine derivatives. Biol Pharm Bull 2003; 262:182-187.
5. Rosentreter, Ulrich, Puls, Walter, Bischoff, Hilmar, United States Patent 44696961982.
6. Breen MP, Bojanowski EM, Cipolle RJ, Dunn WJ, Frank E, Gearien JE. Anticonvulsant activity of substituted benzoyl pyridines. J Pharma Sci 2006; 62:5, 847-849.
7. Lei T, Huger FP, Klein JT, Davis L, Martin LL, Shimshock S, et al. 4-aminopyridine derivatives: A family of novel modulators of voltage-dependent sodium channels. Drug Deve Res 1998; 44:8-13.
8. Katsuki T. Catalytic asymmetric oxidations using optically active (salen) manganese (III) complexes as catalysts. Coordination Chem Rev 1995; 140:189-214.
9. Kelley JL, Koble CS, Davis RG, McLean MS, Soroko FEB, Cooper R. 1-(fluorobenzyl)-4-amino-1H-1,2,3- triazolo [4,5-c]pyridines: synthesis and anticonvulsant activity. J Med Chem 1995; 38:4131.
10. Ravlee I, Sivakumar R, Muruganantham N, Anbalagan N, Gunasekaran V, Leonard JT. Pharmacological evaluation of some new 6-amino/methyl pyridine derivatives. Chem Pharm Bull 2003; 51:2, 162-170.
11. Mosti L, Menozzi G, Schenone P, Dorig, Gaion RM, Belluco P. Synthesis and cardiotonic activity of 2-substituted 5-cyano-1,6-dihydro-6-oxo-3-pyridinecarboxylic acids and their methyl or ethyl esters. Farmaco 1992; 47:427-437.
12. Adsule S, Barve V, Chen D, Ahmed F, Dou QP, Padhye S, et al. Novel schiff base copper complexes of quinoline-2 carboxaldehyde as proteasome inhibitors in human prostate cancer cells. J Med Chem 2006; 49:7242-7246.
13. Grizikfl I, Solov'eva NP, Granik VG, Yuzhakov SD, Dolgun OV, Dugin SF, et al. Synthesis and cardiotonic activity of derivatives of 5-arylhydrazones of 5,6,7,8 tetrahydroquino line-2,5-dione,pyrido[2,3-c]-,and pyrano [2,3-c] carbazole. Pharma Chem J 1995; 29:29-34.
14. Hojo M, Tanaka Y, Katayama O, Teramoto N. Acute antihypertensive effects of the new generation calcium antagonist 3-pyridine carboxylic acid 5-[(cyclopropylamino)-carbonyl]-1, 4-dihydro-2,6-dimethyl-4- (2-nitrophenyl) octyl ester on conscious spontaneously hypertensive rats and renal hypertensive rats. Arzneim-Forsch 1993; 43:847-851.
15. Fisher MH, Lusi A. Imidazo(1,2-a)pyridine anthelmintic and antifungal agents. J Med Chem 1972; 15:982-985.
16. Swiatek P, Malinka W. Anticancer activity of some isothiazolo[5,4-b]pyridine derivatives. Acta Pol Pharm 2004; 6:98-100.
17. Jarrahpour AA, Esmaeilbeig AR, Ardekani AA. Synthesis of 1-(2-aminopyridine)-4-phenyl-1-azabuta-1, 3-diene and 1-(3-aminopyridine)-4-phenyl-1-azabuta-1,3-diene as heterodienes for iron carbonyl complexes. Molbank 2006; M457.
18. Chem. Draw Ultra version 8.0 is a program of Cambridge-Soft Corporation, USA.
19. Perin DD, Armargo WL, Perin DR. In: Purification of Laboratory Chemicals. Pergamon London 1966.
20. Litchfield JT, Wilcoxon FA. Simplified method of evaluating dose effect experiments. J Pharmacol Exp Ther 1949; 96:99-133.
21. Krall RL, Penry JK, White BG, Kupferberg HJ, Swinyard EA. Antiepileptic drug development: History and a program for progress. Epilepsia 1978; 19:409-428.
22. Kupferberg HJ. Antiepileptic drug development program: A cooperative effort of government and industry. Epilepsia 1989; 30:51-56.
23. Swinyard EA. Laboratory evaluation of antiepileptic drugs. Epilepsia 1969; 10:107-119.
24. Löscher W, Fassbender CP, Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. Epilepsy Res 1991; 8:79-94.
25. Löscher W, Nolting B. The role of technical biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. IV. Protective indices. Epilepsy Res 1991; 9:1-10.
26. Dunhm MS, Miya TA, Amer J. A note on a simple apparatus for detecting neurological deficit in rats and mice. Pharm Ass Sci Ed 1957; 46:208.
27. Chiswell B. Synthesis and complexes of unsymmetrical multidentate ligands - part I. Inorg Chim Acta 1979; 35:141.
28. Chiswell B, Crawford JP, O'reilly EJ. Synthesis and complexes of unsymmetrical ligands-partIII- quadridentate ligands. Inorg Chim Acta 1980; 40:223.
29. Pandeya SN, Sriram D, Nath G, DeClercq E. Synthesis, antibacterial, antifungal and anti-HIV activities of schiff and mannich bases derived from isatin derivatives and N-[4-(4′-chlorophenyl) thiazol-2-yl] thiosemicarbazide. Euro J Pharm Sci 1999; 9:25-31.
30. Ismail KZ. Synthesis, spectroscopic, magnetic and biological activity studies of copper(II) complexes of an antipyrine schiff base. Trans Met Chem 2000; 25:522-528.
31. Higson BM, McKenzie ED. The structure, redox properties, and reactions of some planar [MIIN4] chelate compounds of cobalt, nickel, and copper, and their oxidised products, including paramagnetic cobalt(III) species. J Chem Soc Dalton Trans 1972; 269-280.
32. Huseyin U, Kim V D, Silvia C, Santi S, James P S, Paul D, Et al. Synthesis and anticonvulsant activity of 2(3H)-benzoxazolone and 2(3H)-benzothiazolone derivatives. J Med Chem 1998; 41:1138.
33. Dimmock JR, Sidhu KK, Thayer RS, Mack P, Duffy MJ, Reid RS, et al. Anticonvulsant activities of some aryl semicarbazones displaying potent oral activity in the maximal electroshock screen in rats accompanied by high protection indices. J Med Chem 1993; 36:2243-52.
34. Ramanjaneyulu R, Ticku MK. Interactions of pentamethylene tetrazole and tetrazole analogues with the picrotoxinin site of the benzodiazepine-GABA receptor-ionophore complex. Eur J Pharmacol 1984; 98:337-345.
35. Geuris M, Poupaert JH, Scriba GKE, Lambert DM, N- Lambert DM, Mergen, F, et al. (Benzyl-oxycarbonyl) glycine esters and amides as new anticonvulsants. J Med Chem 1998; 41:24-30.